Peter I Croucher
Overview
Explore the profile of Peter I Croucher including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
97
Citations
4238
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
21.
Pereira M, Ko J, Logan J, Protheroe H, Kim K, Tan A, et al.
Elife
. 2020 Jun;
9.
PMID: 32553114
Functional characterisation of cell-type-specific regulatory networks is key to establish a causal link between genetic variation and phenotype. The osteoclast offers a unique model for interrogating the contribution of co-regulated...
22.
Phan T, Croucher P
Nat Rev Cancer
. 2020 Jun;
20(7):398-411.
PMID: 32488200
The success of targeted therapies and immunotherapies has created optimism that cancers may be curable. However, not all patients respond, drug resistance is common and many patients relapse owing to...
23.
Crumbaker M, Chan E, Gong T, Corcoran N, Jaratlerdsiri W, Lyons R, et al.
Cancers (Basel)
. 2020 May;
12(5).
PMID: 32392735
Background: While critical insights have been gained from evaluating the genomic landscape of metastatic prostate cancer, utilizing this information to inform personalized treatment is in its infancy. We performed a...
24.
Owen K, Gearing L, Zanker D, Brockwell N, Khoo W, Roden D, et al.
EMBO Rep
. 2020 Apr;
21(6):e50162.
PMID: 32314873
The latency associated with bone metastasis emergence in castrate-resistant prostate cancer is attributed to dormancy, a state in which cancer cells persist prior to overt lesion formation. Using single-cell transcriptomics...
25.
Summers M, McDonald M, Croucher P
Cold Spring Harb Perspect Med
. 2019 Sep;
10(4).
PMID: 31548220
Recurrent metastasis following extended periods of disease-free survival remains a common cause of morbidity and mortality for many cancer patients. Recurrence is thought to be mediated by tumor cells that...
26.
Gregson C, Bergen D, Leo P, Sessions R, Wheeler L, Hartley A, et al.
J Bone Miner Res
. 2019 Sep;
35(1):92-105.
PMID: 31525280
Novel anabolic drug targets are needed to treat osteoporosis. Having established a large national cohort with unexplained high bone mass (HBM), we aimed to identify a novel monogenic cause of...
27.
Leitch V, Brassill M, Rahman S, Butterfield N, Ma P, Logan J, et al.
Bone
. 2019 Jul;
127:427-435.
PMID: 31306808
Objective: Bone loss in anorexia nervosa and following bariatric surgery is associated with an elevated circulating concentration of the gastrointestinal, anorexigenic hormone, peptide YY (PYY). Selective deletion of the PYY...
28.
Opperman K, Vandyke K, Clark K, Coulter E, Hewett D, Mrozik K, et al.
Neoplasia
. 2019 Jun;
21(8):777-787.
PMID: 31247457
Multiple myeloma is a fatal plasma cell malignancy that is reliant on the bone marrow microenvironment. The bone marrow is comprised of numerous cells of mesenchymal and hemopoietic origin. Of...
29.
Khoo W, Ledergor G, Weiner A, Roden D, Terry R, McDonald M, et al.
Blood
. 2019 Apr;
134(1):30-43.
PMID: 31023703
The era of targeted therapies has seen significant improvements in depth of response, progression-free survival, and overall survival for patients with multiple myeloma. Despite these improvements in clinical outcome, patients...
30.
Horas K, Zheng Y, Fong-Yee C, Macfarlane E, Manibo J, Chen Y, et al.
J Bone Miner Res
. 2019 Apr;
34(9):1721-1732.
PMID: 30995345
Expression of the vitamin D receptor (VDR) is thought to be associated with neoplastic progression. However, the role of the VDR in breast cancer metastasis to bone and the molecular...